https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/659408/solving-aav-s-one-and-done-problem-asgct-highlightshttps://www.biocentury.com/article/659408/solving-aav-s-one-and-done-problem-asgct-highlights?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTSOLVING AAV’S ONE-AND-DONE PROBLEM: ASGCT HIGHLIGHTSStrategies to enable redosing and overcome pre-existing immunity could help revive interest in rare disease gene therapyMon, 11 May 2026 18:12:33 -0700https://www.biocentury.com/article/659426/thin-ice-for-makary-redosing-aavs-a-biocentury-podcasthttps://www.biocentury.com/article/659426/thin-ice-for-makary-redosing-aavs-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWTHIN ICE FOR MAKARY, REDOSING AAVS — A BIOCENTURY PODCAST Who will succeed the FDA commissioner? Plus: American Society of Gene and Cell Therapy highlightsMon, 11 May 2026 17:36:54 -0700https://www.biocentury.com/article/659421/gsk-takes-rights-to-cardiovascular-program-from-china-based-siranbio-deals-reporthttps://www.biocentury.com/article/659421/gsk-takes-rights-to-cardiovascular-program-from-china-based-siranbio-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSGSK TAKES RIGHTS TO CARDIOVASCULAR PROGRAM FROM CHINA-BASED SIRANBIO: DEALS REPORTPlus: Arrowhead/Madrigal, Bayer/Perfuse, and moreMon, 11 May 2026 16:08:47 -0700https://www.biocentury.com/article/659423/entrada-engene-lose-over-half-their-value-on-clinical-readoutshttps://www.biocentury.com/article/659423/entrada-engene-lose-over-half-their-value-on-clinical-readouts?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTENTRADA, ENGENE LOSE OVER HALF THEIR VALUE ON CLINICAL READOUTSBioCentury’s Clinical Report May 6–11Mon, 11 May 2026 15:12:50 -0700https://www.biocentury.com/article/659416/makary-s-grip-slips-at-fda-triggering-speculation-on-successorhttps://www.biocentury.com/article/659416/makary-s-grip-slips-at-fda-triggering-speculation-on-successor?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWMAKARY’S GRIP SLIPS AT FDA, TRIGGERING SPECULATION ON SUCCESSORGraham, Zeta, Diamantas lead list of possible acting commissionersFri, 08 May 2026 15:57:01 -0700https://www.biocentury.com/article/659411/odyssey-completes-journey-to-nasdaq-public-equity-reporthttps://www.biocentury.com/article/659411/odyssey-completes-journey-to-nasdaq-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEODYSSEY COMPLETES JOURNEY TO NASDAQ: PUBLIC EQUITY REPORTPlus: Follow-ons for Cytokinetics, Avalo, Artiva and moreFri, 08 May 2026 15:34:06 -0700https://www.biocentury.com/article/659240/tr1x-inducing-long-term-immune-tolerance-with-allogeneic-tr1-cellshttps://www.biocentury.com/article/659240/tr1x-inducing-long-term-immune-tolerance-with-allogeneic-tr1-cells?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILETR1X: INDUCING LONG-TERM IMMUNE TOLERANCE WITH ALLOGENEIC TR1 CELLSSan Diego biotech is developing off-the-shelf type 1 regulatory T cell therapies for difficult-to-treat I&I diseases, with lead candidate in Phase I/II testingFri, 08 May 2026 15:04:13 -0700https://www.biocentury.com/article/659295/enodia-degrading-secreted-proteins-before-maturationhttps://www.biocentury.com/article/659295/enodia-degrading-secreted-proteins-before-maturation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEENODIA: DEGRADING SECRETED PROTEINS BEFORE MATURATIONArgobio’s third seed company is developing SEC61-targeted degraders that block disease-driving proteins before they enter the secretory pathwayFri, 08 May 2026 14:15:23 -0700https://www.biocentury.com/article/659319/two-mechanisms-vie-to-deliver-first-hypoxic-ischemic-encephalopathy-drughttps://www.biocentury.com/article/659319/two-mechanisms-vie-to-deliver-first-hypoxic-ischemic-encephalopathy-drug?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTWO MECHANISMS VIE TO DELIVER FIRST HYPOXIC ISCHEMIC ENCEPHALOPATHY DRUGReAlta aims to shut down a pathological cascade, while Pharmazz seeks to restart a developmental programThu, 07 May 2026 15:23:19 -0700https://www.biocentury.com/article/659403/mounjaro-overtakes-keytruda-for-the-first-timehttps://www.biocentury.com/article/659403/mounjaro-overtakes-keytruda-for-the-first-time?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEMOUNJARO OVERTAKES KEYTRUDA FOR THE FIRST TIMELilly’s diabetes brand alone outsold Keytruda in 1Q26, while combined tirzepatide sales topped the cancer drug by nearly $5B in FY25Thu, 07 May 2026 15:20:19 -0700https://www.biocentury.com/article/659394/cellcentric-syndicate-expands-ahead-of-phase-iii-myeloma-push-venture-reporthttps://www.biocentury.com/article/659394/cellcentric-syndicate-expands-ahead-of-phase-iii-myeloma-push-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCECELLCENTRIC SYNDICATE EXPANDS AHEAD OF PHASE III MYELOMA PUSH: VENTURE REPORTPlus: Blackstone backs pancreatic insufficiency play Anagram; Banyan raises new fund; and moreThu, 07 May 2026 14:02:59 -0700https://www.biocentury.com/article/659405/angelini-builds-u-s-commercial-ops-via-4-1b-catalyst-acquisitionhttps://www.biocentury.com/article/659405/angelini-builds-u-s-commercial-ops-via-4-1b-catalyst-acquisition?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSANGELINI BUILDS U.S. COMMERCIAL OPS VIA $4.1B CATALYST ACQUISITIONItalian pharma adds drugs for rare neurological diseases, sales infrastructureThu, 07 May 2026 11:37:53 -0700https://www.biocentury.com/article/659392/science-spotlight-new-prime-editing-tools-for-large-dna-insertionshttps://www.biocentury.com/article/659392/science-spotlight-new-prime-editing-tools-for-large-dna-insertions?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: NEW PRIME EDITING TOOLS FOR LARGE DNA INSERTIONSBioCentury’s roundup of translational innovations also includes two ways to enhance T cell functionWed, 06 May 2026 16:18:12 -0700https://www.biocentury.com/article/659395/aura-names-natalie-holles-ceo-and-other-biotech-management-moveshttps://www.biocentury.com/article/659395/aura-names-natalie-holles-ceo-and-other-biotech-management-moves?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSAURA NAMES NATALIE HOLLES CEO, AND OTHER BIOTECH MANAGEMENT MOVESTwo new partners for Jeito; Xin Tao returns to Wed, 06 May 2026 15:55:24 -0700https://www.biocentury.com/article/659390/the-race-for-speed-can-europe-compete-to-be-a-bigger-phase-i-hubhttps://www.biocentury.com/article/659390/the-race-for-speed-can-europe-compete-to-be-a-bigger-phase-i-hub?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTHE RACE FOR SPEED: CAN EUROPE COMPETE TO BE A BIGGER PHASE I HUB?Bio€quity Europe Scene Setter examines trends in Phase I clinical trials, with a focus on EuropeWed, 06 May 2026 14:48:08 -0700https://www.biocentury.com/article/659379/fda-s-april-approvals-include-slimmer-label-for-xpovio-two-nmeshttps://www.biocentury.com/article/659379/fda-s-april-approvals-include-slimmer-label-for-xpovio-two-nmes?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEFDA’S APRIL APPROVALS INCLUDE SLIMMER LABEL FOR XPOVIO, TWO NMESsNDA removed Xpovio’s accelerated approval in DLBCL; NME count reaches 12 for 2026Wed, 06 May 2026 14:43:05 -0700https://www.biocentury.com/article/659383/at-least-five-pdufa-dates-on-fda-s-may-dockethttps://www.biocentury.com/article/659383/at-least-five-pdufa-dates-on-fda-s-may-docket?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEAT LEAST FIVE PDUFA DATES ON FDA’S MAY DOCKETOne new product via 505(b)(2), plus four label expansionsTue, 05 May 2026 16:39:10 -0700https://www.biocentury.com/article/659376/cytokinetics-scores-late-stage-win-in-non-obstructive-hcm-as-bms-plans-camzyos-restarthttps://www.biocentury.com/article/659376/cytokinetics-scores-late-stage-win-in-non-obstructive-hcm-as-bms-plans-camzyos-restart?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTCYTOKINETICS SCORES LATE-STAGE WIN IN NON-OBSTRUCTIVE HCM AS BMS PLANS CAMZYOS RESTARTBioCentury’s Clinical Report April 28–May 5Tue, 05 May 2026 16:19:00 -0700https://www.biocentury.com/article/659352/revmed-maps-its-next-ras-frontierhttps://www.biocentury.com/article/659352/revmed-maps-its-next-ras-frontier?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTREVMED MAPS ITS NEXT RAS FRONTIERPoised to overhaul PDAC care, RevMed’s longer-term vision spans catalytic inhibition, immune modulation and disease interceptionTue, 05 May 2026 15:32:10 -0700https://www.biocentury.com/article/659113/europe-s-phase-i-trials-see-spain-u-k-lead-hot-spotshttps://www.biocentury.com/article/659113/europe-s-phase-i-trials-see-spain-u-k-lead-hot-spots?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEEUROPE’S PHASE I TRIALS SEE SPAIN, U.K. LEAD HOT SPOTSBio€quity Europe preview: Scene Setter analyzes European Phase I trials from 2021-25Tue, 05 May 2026 08:28:42 -0700https://www.biocentury.com/article/657728/cytospire-broadening-tumor-killing-with-pan-t-cell-engagershttps://www.biocentury.com/article/657728/cytospire-broadening-tumor-killing-with-pan-t-cell-engagers?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILECYTOSPIRE: BROADENING TUMOR KILLING WITH PAN-ΓΔ T CELL ENGAGERSLondon-based biotech is advancing toward the clinic with a new $83M series A roundTue, 05 May 2026 00:04:34 -0700https://www.biocentury.com/article/659365/ucb-s-candid-buy-grand-rounds-ipos-and-leukodystrophy-a-biocentury-podcasthttps://www.biocentury.com/article/659365/ucb-s-candid-buy-grand-rounds-ipos-and-leukodystrophy-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSUCB’S CANDID BUY, GRAND ROUNDS, IPOS AND LEUKODYSTROPHY — A BIOCENTURY PODCAST$2B takeout for San Diego company keeps T cell engagers in the spotlightMon, 04 May 2026 17:42:06 -0700https://www.biocentury.com/article/659354/backing-out-of-merger-t-cell-engager-play-candid-chooses-ucb-s-2b-bidhttps://www.biocentury.com/article/659354/backing-out-of-merger-t-cell-engager-play-candid-chooses-ucb-s-2b-bid?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSBACKING OUT OF MERGER, T CELL ENGAGER PLAY CANDID CHOOSES UCB’S $2B BIDRiding growth from new blockbuster, Belgian biopharma builds with another dealMon, 04 May 2026 17:25:29 -0700https://www.biocentury.com/article/659362/19-m-a-deals-over-1b-in-1h26https://www.biocentury.com/article/659362/19-m-a-deals-over-1b-in-1h26?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTE19 M&A DEALS OVER $1B IN 1H26Five weeks into 2Q26, nine deals have already been announced, with no signs of slowingMon, 04 May 2026 16:19:46 -0700https://www.biocentury.com/article/659368/big-week-for-biotech-m-a-brings-seven-transactions-deals-reporthttps://www.biocentury.com/article/659368/big-week-for-biotech-m-a-brings-seven-transactions-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSBIG WEEK FOR BIOTECH M&A BRINGS SEVEN TRANSACTIONS: DEALS REPORTPlus: Lilly signs a $2.3 billion discovery dealMon, 04 May 2026 16:01:34 -0700https://www.biocentury.com/article/659316/genomics-trailblazer-venter-passes-awayhttps://www.biocentury.com/article/659316/genomics-trailblazer-venter-passes-away?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSGENOMICS TRAILBLAZER VENTER PASSES AWAYPlus updates from Cue, Galapagos and moreFri, 01 May 2026 17:04:48 -0700https://www.biocentury.com/article/659349/proposed-ban-on-china-clinical-trial-data-reflects-deep-concerns-in-washingtonhttps://www.biocentury.com/article/659349/proposed-ban-on-china-clinical-trial-data-reflects-deep-concerns-in-washington?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWPROPOSED BAN ON CHINA CLINICAL TRIAL DATA REFLECTS DEEP CONCERNS IN WASHINGTONThough unlikely to be adopted, the measure signals strong congressional interest in responding to competition from ChinaFri, 01 May 2026 16:17:55 -0700https://www.biocentury.com/article/659345/three-biotechs-raise-850m-in-upsized-ipos-gain-in-aftermarket-public-equity-reporthttps://www.biocentury.com/article/659345/three-biotechs-raise-850m-in-upsized-ipos-gain-in-aftermarket-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCETHREE BIOTECHS RAISE $850M+ IN UPSIZED IPOS, GAIN IN AFTERMARKET: PUBLIC EQUITY REPORTPlus: Data drive follow-ons for Oruka, Veradermics, Intellia; PIPE supports in-licensing deal as Cue welcomes new CEO; and moreFri, 01 May 2026 14:37:07 -0700https://www.biocentury.com/article/658995/mapping-leukodystrophy-pipelines-by-disease-biologyhttps://www.biocentury.com/article/658995/mapping-leukodystrophy-pipelines-by-disease-biology?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMAPPING LEUKODYSTROPHY PIPELINES BY DISEASE BIOLOGYAn analysis of 11 genetically defined white matter disorders and the modalities being matched to their underlying defectsFri, 01 May 2026 13:52:22 -0700https://www.biocentury.com/article/659339/fda-up-close-and-personal-a-banker-s-recalibrationhttps://www.biocentury.com/article/659339/fda-up-close-and-personal-a-banker-s-recalibration?utm_source=bc_rss&utm_medium=rssBIOCENTURY | GUEST COMMENTARYFDA, UP CLOSE AND PERSONAL: A BANKER’S RECALIBRATIONA former agency advisor’s view from inside FDA: What industry often misreads as dysfunction is rooted in caution, independence and process disciplineThu, 30 Apr 2026 17:49:13 -0700https://www.biocentury.com/article/659341/raising-the-bar-on-causal-biology-syncona-s-chris-hollowoodhttps://www.biocentury.com/article/659341/raising-the-bar-on-causal-biology-syncona-s-chris-hollowood?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONRAISING THE BAR ON CAUSAL BIOLOGY — SYNCONA’S CHRIS HOLLOWOODHow evolving discovery, and a strategic pivot, are driving Syncona’s investments thesis on gene therapies and elsewhereThu, 30 Apr 2026 17:01:22 -0700https://www.biocentury.com/article/659337/galapagos-spinout-coultreon-draws-125m-to-test-sik3-inhibitor-venture-reporthttps://www.biocentury.com/article/659337/galapagos-spinout-coultreon-draws-125m-to-test-sik3-inhibitor-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEGALAPAGOS SPINOUT COULTREON DRAWS $125M TO TEST SIK3 INHIBITOR: VENTURE REPORTPlus: Pair of European microbiome companies draw rounds; Apuri backs Sigmeta; and moreThu, 30 Apr 2026 14:39:41 -0700https://www.biocentury.com/article/659214/science-spotlight-making-in-vivo-car-t-less-immunogenichttps://www.biocentury.com/article/659214/science-spotlight-making-in-vivo-car-t-less-immunogenic?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: MAKING IN VIVO CAR T LESS IMMUNOGENICPlus: BACH1 skews neuronal fate in Down syndrome, and optimized prime editors drive large genomic insertionsThu, 30 Apr 2026 14:30:51 -0700https://www.biocentury.com/article/659327/tiny-biotech-s-experience-raises-questions-about-fda-s-rare-disease-policieshttps://www.biocentury.com/article/659327/tiny-biotech-s-experience-raises-questions-about-fda-s-rare-disease-policies?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONTINY BIOTECH’S EXPERIENCE RAISES QUESTIONS ABOUT FDA’S RARE DISEASE POLICIESGrace Science says it has been shut out of plausible mechanism framework, denied flexibility on CMC requirementsWed, 29 Apr 2026 15:11:29 -0700https://www.biocentury.com/article/659321/in-chiesi-s-biggest-m-a-deal-yet-pharma-buys-hae-company-kalvistahttps://www.biocentury.com/article/659321/in-chiesi-s-biggest-m-a-deal-yet-pharma-buys-hae-company-kalvista?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSIN CHIESI’S BIGGEST M&A DEAL YET, PHARMA BUYS HAE COMPANY KALVISTAItalian company adds another rare disease asset via $1.9B takeoutWed, 29 Apr 2026 14:48:39 -0700https://www.biocentury.com/article/659325/a-year-after-tourette-s-readout-teva-pays-700m-up-front-for-vc-backed-emalexhttps://www.biocentury.com/article/659325/a-year-after-tourette-s-readout-teva-pays-700m-up-front-for-vc-backed-emalex?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSA YEAR AFTER TOURETTE’S READOUT, TEVA PAYS $700M UP FRONT FOR VC-BACKED EMALEXSeeing potential growth driver, pharma adds ‘NDA-ready’ asset for pediatric neurological disorderWed, 29 Apr 2026 14:38:50 -0700https://www.biocentury.com/article/659324/prvs-still-pricey-despite-renewalhttps://www.biocentury.com/article/659324/prvs-still-pricey-despite-renewal?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEPRVS STILL PRICEY DESPITE RENEWALTwo priority review vouchers have sold since the rare pediatric program was extendedWed, 29 Apr 2026 13:49:41 -0700https://www.biocentury.com/article/659269/aurora-making-bespoke-base-editing-commercially-viablehttps://www.biocentury.com/article/659269/aurora-making-bespoke-base-editing-commercially-viable?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEAURORA: MAKING BESPOKE BASE EDITING COMMERCIALLY VIABLEBacked by $16 million in seed funding from Menlo, Aurora is starting with PKU as proving groundTue, 28 Apr 2026 16:06:42 -0700https://www.biocentury.com/article/659285/kurma-s-latest-fundraise-highlights-challenges-for-early-stage-vcshttps://www.biocentury.com/article/659285/kurma-s-latest-fundraise-highlights-challenges-for-early-stage-vcs?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEKURMA’S LATEST FUNDRAISE HIGHLIGHTS CHALLENGES FOR EARLY-STAGE VCSEuropean investor closes new fund at €215M — a 34% increase over its predecessor — with half earmarked for company creationTue, 28 Apr 2026 15:33:48 -0700https://www.biocentury.com/article/659306/new-targets-uncovered-at-aacrhttps://www.biocentury.com/article/659306/new-targets-uncovered-at-aacr?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONNEW TARGETS UNCOVERED AT AACR BioCentury’s list of 172 new targets from this year’s American Association for Cancer Research abstractsTue, 28 Apr 2026 15:10:08 -0700https://www.biocentury.com/article/659287/lilly-s-deal-spree-continues-with-ajax-takeout-deals-reporthttps://www.biocentury.com/article/659287/lilly-s-deal-spree-continues-with-ajax-takeout-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSLILLY’S DEAL SPREE CONTINUES WITH AJAX TAKEOUT: DEALS REPORTPlus: Sun buying Organon; BeOne in trispecifics deal with Huahui; and moreMon, 27 Apr 2026 18:23:37 -0700https://www.biocentury.com/article/659293/intellia-s-late-stage-win-tees-up-market-test-case-for-in-vivo-crisprhttps://www.biocentury.com/article/659293/intellia-s-late-stage-win-tees-up-market-test-case-for-in-vivo-crispr?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTINTELLIA’S LATE-STAGE WIN TEES UP MARKET TEST CASE FOR IN VIVO CRISPRBioCentury’s clinical report April 21-27Mon, 27 Apr 2026 18:21:18 -0700https://www.biocentury.com/article/659296/immune-enhancing-mechanisms-define-new-oncology-targets-at-aacrhttps://www.biocentury.com/article/659296/immune-enhancing-mechanisms-define-new-oncology-targets-at-aacr?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONIMMUNE-ENHANCING MECHANISMS DEFINE NEW ONCOLOGY TARGETS AT AACRBioCentury identified 172 new targets at AACR 2026Mon, 27 Apr 2026 18:18:34 -0700https://www.biocentury.com/article/659298/new-targets-at-aacr-biopharma-deals-kurma-fund-a-biocentury-podcasthttps://www.biocentury.com/article/659298/new-targets-at-aacr-biopharma-deals-kurma-fund-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTNEW TARGETS AT AACR, BIOPHARMA DEALS, KURMA FUND — A BIOCENTURY PODCAST Target discovery, pan-RAS ADCs at the American Association for Cancer ResearchMon, 27 Apr 2026 17:40:10 -0700https://www.biocentury.com/article/659291/new-data-suggest-oruka-s-il-23-mab-could-be-competitive-in-psoriasishttps://www.biocentury.com/article/659291/new-data-suggest-oruka-s-il-23-mab-could-be-competitive-in-psoriasis?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTENEW DATA SUGGEST ORUKA’S IL-23 MAB COULD BE COMPETITIVE IN PSORIASIS Phase IIa results show high PASI 100 rates for half-life-extended ORKA-001, but durability and quality-of-life data still pendingMon, 27 Apr 2026 16:40:11 -0700https://www.biocentury.com/article/659276/inventiva-reloads-c-suite-as-it-looks-to-readouthttps://www.biocentury.com/article/659276/inventiva-reloads-c-suite-as-it-looks-to-readout?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSINVENTIVA RELOADS C-SUITE AS IT LOOKS TO READOUTNew CEO for Santhera and moreFri, 24 Apr 2026 16:55:34 -0700https://www.biocentury.com/article/659275/ema-s-chmp-backs-sanofi-btk-inhibitor-rebuffed-by-fdahttps://www.biocentury.com/article/659275/ema-s-chmp-backs-sanofi-btk-inhibitor-rebuffed-by-fda?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEEMA’S CHMP BACKS SANOFI BTK INHIBITOR REBUFFED BY FDAPlus positive opinions in April on Fri, 24 Apr 2026 16:53:10 -0700https://www.biocentury.com/article/659271/nektar-parlays-alopecia-readout-into-374m-follow-on-public-equity-reporthttps://www.biocentury.com/article/659271/nektar-parlays-alopecia-readout-into-374m-follow-on-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCENEKTAR PARLAYS ALOPECIA READOUT INTO $374M FOLLOW-ON: PUBLIC EQUITY REPORTPlus: AnaptysBio’s autoimmune spinout First Tracks Bio arrives on NASDAQ; and moreFri, 24 Apr 2026 15:40:55 -0700https://www.biocentury.com/article/659261/the-podcaster-to-policy-pathway-poses-risks-to-patients-innovationhttps://www.biocentury.com/article/659261/the-podcaster-to-policy-pathway-poses-risks-to-patients-innovation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYTHE PODCASTER-TO-POLICY PATHWAY POSES RISKS TO PATIENTS, INNOVATIONThe Trump administration’s moves on peptides and psychedelics should alarm everyone, not least small biotechsFri, 24 Apr 2026 12:04:09 -0700https://www.biocentury.com/article/659256/milestones-mounting-in-biotech-m-ahttps://www.biocentury.com/article/659256/milestones-mounting-in-biotech-m-a?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEMILESTONES MOUNTING IN BIOTECH M&ASince mid-2024 55% of deals $500M+ had CVRs or other contingent paymentsThu, 23 Apr 2026 17:35:26 -0700